Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective

Thierry Rolling; Tsiri Agbenyega; Sanjeev Krishna; Peter G Kremsner; Jakob P Cramer

doi:10.1016/j.tmaid.2015.03.003

Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective

Standard

Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective. / Rolling, Thierry; Agbenyega, Tsiri; Krishna, Sanjeev; Kremsner, Peter G; Cramer, Jakob P.

in: TRAVEL MED INFECT DI, Jahrgang 13, Nr. 2, 31.03.2015, S. 143-149.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rolling, T, Agbenyega, T, Krishna, S, Kremsner, PG & Cramer, JP 2015, 'Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective', TRAVEL MED INFECT DI, Jg. 13, Nr. 2, S. 143-149. https://doi.org/10.1016/j.tmaid.2015.03.003

APA

Rolling, T., Agbenyega, T., Krishna, S., Kremsner, P. G., & Cramer, J. P. (2015). Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective. TRAVEL MED INFECT DI, 13(2), 143-149. https://doi.org/10.1016/j.tmaid.2015.03.003

Vancouver

Rolling T, Agbenyega T, Krishna S, Kremsner PG, Cramer JP. Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective. TRAVEL MED INFECT DI. 2015 Mär 31;13(2):143-149. https://doi.org/10.1016/j.tmaid.2015.03.003

Bibtex

@article{de4aa29e45a54249967a51d62d837e77,

title = "Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective",

abstract = "Artesunate has replaced quinine as the recommended first-line treatment of severe malaria as it clears parasites faster and lowers mortality. After artesunate's introduction, however, reports of delayed haemolysis have emerged. Typically, this adverse haemolytic event peaks two to three weeks after the acute phase of malaria, and can be severe enough to make blood transfusions necessary in the management of some patients. Delayed haemolysis has been detected in prospective studies in 7-21% of patients treated with artesunate. A confirmed risk factor in travellers is hyperparasitaemia, while additional in malaria-endemic countries young age has been shown to increase risk. The pathophysiology of this phenomenon has not yet been fully elucidated, but may include various combinations of delayed destruction of {"}pitted{"} erythrocytes and autoimmune aetiology. All patients treated with parenteral artesunate should be followed up for at least four weeks to detect signs of haemolysis and to allow appropriate symptomatic treatment.",

author = "Thierry Rolling and Tsiri Agbenyega and Sanjeev Krishna and Kremsner, {Peter G} and Cramer, {Jakob P}",

note = "Copyright {\textcopyright} 2015. Published by Elsevier Ltd.",

year = "2015",

month = mar,

day = "31",

doi = "10.1016/j.tmaid.2015.03.003",

language = "English",

volume = "13",

pages = "143--149",

journal = "TRAVEL MED INFECT DI",

issn = "1477-8939",

publisher = "Elsevier USA",

number = "2",

}

RIS

TY - JOUR

T1 - Delayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective

AU - Rolling, Thierry

AU - Agbenyega, Tsiri

AU - Krishna, Sanjeev

AU - Kremsner, Peter G

AU - Cramer, Jakob P

PY - 2015/3/31

Y1 - 2015/3/31

N2 - Artesunate has replaced quinine as the recommended first-line treatment of severe malaria as it clears parasites faster and lowers mortality. After artesunate's introduction, however, reports of delayed haemolysis have emerged. Typically, this adverse haemolytic event peaks two to three weeks after the acute phase of malaria, and can be severe enough to make blood transfusions necessary in the management of some patients. Delayed haemolysis has been detected in prospective studies in 7-21% of patients treated with artesunate. A confirmed risk factor in travellers is hyperparasitaemia, while additional in malaria-endemic countries young age has been shown to increase risk. The pathophysiology of this phenomenon has not yet been fully elucidated, but may include various combinations of delayed destruction of "pitted" erythrocytes and autoimmune aetiology. All patients treated with parenteral artesunate should be followed up for at least four weeks to detect signs of haemolysis and to allow appropriate symptomatic treatment.

AB - Artesunate has replaced quinine as the recommended first-line treatment of severe malaria as it clears parasites faster and lowers mortality. After artesunate's introduction, however, reports of delayed haemolysis have emerged. Typically, this adverse haemolytic event peaks two to three weeks after the acute phase of malaria, and can be severe enough to make blood transfusions necessary in the management of some patients. Delayed haemolysis has been detected in prospective studies in 7-21% of patients treated with artesunate. A confirmed risk factor in travellers is hyperparasitaemia, while additional in malaria-endemic countries young age has been shown to increase risk. The pathophysiology of this phenomenon has not yet been fully elucidated, but may include various combinations of delayed destruction of "pitted" erythrocytes and autoimmune aetiology. All patients treated with parenteral artesunate should be followed up for at least four weeks to detect signs of haemolysis and to allow appropriate symptomatic treatment.

U2 - 10.1016/j.tmaid.2015.03.003

DO - 10.1016/j.tmaid.2015.03.003

M3 - SCORING: Journal article

C2 - 25812775

VL - 13

SP - 143

EP - 149

JO - TRAVEL MED INFECT DI

JF - TRAVEL MED INFECT DI

SN - 1477-8939

IS - 2

ER -